Companies

MSN inks license pact with DRDO for manufacturing, distribution and marketing of 2-DG

Our Bureau Hyderabad | Updated on July 09, 2021

Hyderabad-based MSN Labs will be launching the 2-DG as a twice-a-day product in sachet form

MSN Laboratories has entered into a license agreement with Defence Research & Development Establishment (DRDE) and Institute of Nuclear Medicine and Allied Sciences (INMAS) — establishments of the Defence Research & Development Organisation (DRDO) — for the manufacturing, distribution and marketing of 2- Deoxy-D-Glucose (2-DG) in India.

Hyderabad-based MSN Labs will be launching the 2-DG as a twice-a-day product in sachet form under the brand name MSN 2D, in strength of 2.34 g.

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe Covid-19 patients.

MSN is now conducting clinical trials with investigational drugs like Aviptadil on severe hospitalised patients and with Molnupiravir on mild and moderate Covid patients, according to a release.

Published on July 09, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor